hCG
Placental glycoprotein hormone that acts as an LH-receptor agonist — used clinically as an ovulation trigger in IVF and off-label in men to stimulate endogenous testosterone and preserve fertility during or after exogenous androgen use.
hCG is a placental hormone that binds the same receptor as LH, so it works as a long-acting LH substitute — one injection sustains a signal for days where natural LH lasts minutes. That gives it two legitimate jobs: triggering final egg maturation in IVF, and telling the testes to make testosterone and sperm when the brain’s signal is missing or has been switched off by testosterone replacement. The TRT use is the one most people search for, and it is well quantified: testosterone alone drops intratesticular testosterone by 94%, and 250 to 500 IU of hCG every other day restores it to around or above baseline. The third thing hCG is famous for, the Simeons hCG diet, has been tested against placebo repeatedly since 1976 and has never beaten it — the weight loss comes from the 500 kcal/day diet, and the FDA and FTC declared over-the-counter homeopathic hCG products illegal in 2011.
What is hCG?
Human chorionic gonadotropin (hCG) is a 237-amino-acid heterodimeric glycoprotein hormone composed of an alpha subunit (shared with LH, FSH, and TSH) non-covalently linked to a beta subunit nearly identical to the beta subunit of luteinizing hormone. It is produced by the syncytiotrophoblast cells of the placenta during pregnancy — detection of hCG in blood or urine is the basis of every modern pregnancy test — and it binds the same receptor as LH (the LH/hCG receptor, LHCGR). In clinical medicine, hCG has two well-established roles: as a final ovulation trigger in IVF and other assisted reproduction cycles (marketed as Ovidrel/Ovitrelle in its recombinant form, and as Pregnyl and Novarel as urinary-derived preparations), and as an LH-mimetic drug in men to stimulate Leydig-cell testosterone production in hypogonadotropic hypogonadism, delayed puberty, cryptorchidism, and off-label for preserving testicular function and fertility during exogenous testosterone use or after anabolic-androgenic steroid use. It is also a consumer search magnet for a third, entirely different context — the discredited Simeons "hCG diet" for weight loss — which is addressed honestly below but is not supported by controlled trials.
What hCG Is Investigated For
hCG has two clinically legitimate centers of gravity and one persistent consumer myth. The legitimate uses are ovulation induction / IVF trigger in women and Leydig-cell stimulation in men with hypogonadotropic hypogonadism — both with decades of strong evidence and FDA-approved products. Its highest-traffic off-label use is in men on testosterone replacement therapy (TRT) or recovering from anabolic-androgenic steroid cycles: low-dose hCG added to testosterone preserves intratesticular testosterone and sperm production (Coviello et al., 2005; and the 2013 Hsieh et al. analysis showing no patient became azoospermic on concomitant TRT plus 500 IU hCG every other day). The myth is the 1954 Simeons "hCG diet" combining hCG injections with a 500 kcal/day diet — repeatedly tested in placebo-controlled trials and a 1995 criteria-based meta-analysis, all finding hCG no better than placebo; any weight loss comes from the extreme calorie restriction, not the hormone. In 2011 the FDA and FTC jointly moved against over-the-counter "homeopathic hCG" drops and pellets as illegal and fraudulent. Treat legitimate hCG use as an endocrine drug requiring clinician oversight; treat the hCG diet as debunked.
History & Discovery
hCG was identified in the 1920s by Selmar Aschheim and Bernhard Zondek at the Charité in Berlin. Their "A-Z test" — injecting the urine of a suspected pregnant woman into immature female mice and observing ovarian follicular response within days — was the first reliable pregnancy test and the first clear demonstration that a gonad-stimulating substance was present in pregnancy urine. Over the following decades, hCG was purified from pooled pregnancy urine for clinical use, and the sequencing of the alpha and beta subunits in the 1970s (work by Canfield, Ross, and others) established the structural relationship between hCG and LH, FSH, and TSH. Clinical use in the 20th century centered on ovulation induction in combination with gonadotropin therapy for infertility, on cryptorchidism in boys, and on inducing testicular descent and pubertal development in hypogonadotropic hypogonadism. Recombinant choriogonadotropin alfa (Ovidrel / Ovitrelle) was developed by Serono and approved by the FDA in 2000, eliminating the need for pooled urine collection and providing a more consistent potency standard. Urinary-derived preparations — Pregnyl (Organon) and Novarel (Ferring) — remain in use, particularly for men's-health indications where the higher total IU count per vial is clinically useful. The Simeons hCG diet emerged in 1954, when the British physician Albert T. W. Simeons, working in Rome, published "The action of chorionic gonadotrophin in the obese" in The Lancet, describing daily hCG injections combined with a 500 kcal/day diet for obesity. His separately circulated protocol manuscript "Pounds and Inches" — which is what most modern clinics actually copy — set the regimen out in detail. His claims — that hCG specifically mobilized "abnormal fat," reduced hunger, and reshaped the body — were empirically tested in the decades that followed and repeatedly failed to separate from placebo. A 1976 trial by Stein et al. and a 1990 trial by Bosch et al. both used identical very-low-calorie diets in hCG and placebo arms and found no difference in weight loss; a 1995 criteria-based meta-analysis by Lijesen and colleagues in the British Journal of Clinical Pharmacology concluded there was no scientific evidence that hCG produced weight loss beyond caloric restriction. Despite this, the diet was resurrected in consumer weight-loss clinics in the 2000s and paired with homeopathic hCG drops, pellets, and sprays sold over the counter. In December 2011, the FDA and FTC took joint action, declaring those products illegal and fraudulent and ordering them off the market. The underlying endocrine use of hCG was never in question — only the diet application.
How It Works
hCG is a hormone the placenta makes during pregnancy, and it looks enough like LH — the pituitary hormone that tells the testes and ovaries what to do — that it binds the same receptor. In women undergoing IVF, a single shot of hCG triggers the egg to finish maturing and ovulate. In men, hCG tells the testes to make testosterone and sperm directly, bypassing the brain's signal. That makes it useful when the brain's signal is missing (hypogonadotropic hypogonadism) or has been shut off by exogenous testosterone or steroid use.
hCG is a 237-amino-acid heterodimeric glycoprotein consisting of a 92-amino-acid alpha subunit (shared with LH, FSH, and TSH) and a 145-amino-acid beta subunit homologous to LH-beta but with an additional carboxy-terminal peptide extension bearing four O-linked glycans. This extension slows renal clearance and gives hCG a plasma half-life of roughly 24–36 hours, compared to ~20 minutes for LH. Both hormones bind the LH/choriogonadotropin receptor (LHCGR), a Gs-coupled G-protein-coupled receptor expressed on ovarian theca and granulosa cells, testicular Leydig cells, and corpus luteum. Receptor activation drives adenylyl cyclase, elevates cAMP, activates PKA, and upregulates the steroidogenic cascade — StAR, CYP11A1, CYP17A1, HSD3B, CYP19A1 — producing progesterone and estrogens in the ovary and testosterone in Leydig cells. In women, a pharmacologic hCG dose at late follicular phase substitutes for the endogenous LH surge, triggering oocyte meiotic resumption and ovulation roughly 36 hours later. In men, exogenous hCG acts as a long-acting LH replacement, driving intratesticular testosterone concentrations that support spermatogenesis even when pituitary LH is suppressed by exogenous androgens. Recombinant choriogonadotropin alfa (Ovidrel) and urinary-derived hCG (Pregnyl, Novarel) are pharmacodynamically similar in clinical use, with recombinant product offering more consistent potency and purity.
Evidence Snapshot
Human Clinical Evidence
Extensive across multiple indications. hCG triggering is the long-established standard of care in IVF rather than a question still under test; the relevant Cochrane review (18 RCTs, 2952 women) addresses which hCG to use, finding no difference between recombinant and urinary preparations for live birth, ongoing pregnancy or OHSS. Strong evidence for Leydig-cell stimulation in men, including Coviello et al. demonstrating dose-dependent maintenance of intratesticular testosterone and Hsieh et al. (2013) showing preservation of spermatogenesis with 500 IU intramuscularly every other day concomitant with TRT. Multiple placebo-controlled trials (Bosch 1990; Stein 1976) and the 1995 Lijesen meta-analysis confirm hCG is no better than placebo for weight loss.
Animal / Preclinical
Comprehensive. hCG has been used in livestock reproductive biology for decades, and its effect on LHCGR, steroidogenesis, and gonadal function is thoroughly characterized in rodents and larger mammals.
Mechanistic Rationale
Very strong. LHCGR biology, hCG structure, and the pharmacology of LH-receptor agonism are among the most thoroughly mapped areas of reproductive endocrinology.
Research Gaps & Open Questions
What the current literature has not yet settled about hCG:
- 01Long-term safety of continuous low-dose hCG as a TRT adjunct has never been characterized in a controlled trial. The dosing everyone uses comes from Coviello 2005, which ran for three weeks and measured intratesticular testosterone rather than clinical outcomes, yet men take it alongside testosterone for years.
- 02Whether maintaining intratesticular testosterone with hCG actually preserves long-term fertility, as opposed to preserving the biochemical and semen-parameter markers of it, has not been tested against live-birth endpoints.
- 03Optimal hCG dosing and duration for recovery after anabolic-androgenic steroid use is entirely empirical. The 2014 Rahnema review was intended as a meta-analysis but found no studies meeting its quality threshold, and that has not materially changed.
- 04Whether hCG monotherapy is a viable alternative to testosterone replacement in late-onset hypogonadism, rather than an adjunct to it, rests on a single 40-patient randomized comparison and has never been replicated at scale.
- 05The long-term consequences for children conceived after high-dose hCG triggering are an open question rather than a settled one. The 2026 Nature Communications work pairs observational human cohorts with a mouse rescue experiment, but no prospective human follow-up has tested whether lowering the trigger dose changes offspring outcomes.
- 06Dual triggering is widely used on the strength of oocyte-yield improvements that have not reliably converted into higher live-birth rates, and the 2026 data in poor responders are negative. Which patients genuinely benefit is unresolved.
- 07There is no head-to-head trial of hCG against enclomiphene or kisspeptin for preserving fertility during androgen use, despite all three being promoted for that purpose.
Forms & Administration
hCG is administered by subcutaneous or intramuscular injection. Recombinant choriogonadotropin alfa (Ovidrel) comes as a pre-filled 250 mcg syringe for a single IVF trigger dose. Urinary-derived hCG (Pregnyl, Novarel) is supplied as a lyophilized powder reconstituted with bacteriostatic water or saline. Novarel is currently marketed in 5,000 and 10,000 IU vials, while the only Pregnyl presentation still listed as active is the 10,000 IU vial. For men on TRT or in PCT, low-dose protocols (commonly 500 IU 2–3 times weekly) use reconstituted vials stored refrigerated and drawn with an insulin-gauge syringe. hCG should only be used under the supervision of a qualified clinician who can select the indication, choose product, and manage monitoring.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
IVF ovulation trigger: single dose of 250 mcg recombinant choriogonadotropin alfa (Ovidrel) subcutaneously, or 5,000–10,000 IU urinary-derived hCG intramuscularly, given 34–36 hours before planned oocyte retrieval. Male hypogonadotropic hypogonadism: 1,500–5,000 IU 2–3 times weekly by IM or SC injection, often combined with recombinant FSH for fertility induction. TRT adjunct for fertility / testicular preservation: 500 IU every other day, given intramuscularly in the Hsieh et al. (2013) series (Coviello et al. 2005 tested 125–500 IU every other day), sometimes 250–500 IU 2–3 times weekly. Post-cycle therapy after anabolic steroid use: empirical protocols typically 1,000–2,500 IU every other day for 2–4 weeks, often followed by a SERM (clomiphene or tamoxifen) to stimulate recovery of the pituitary signal once the testes have been "primed."
Frequency
IVF trigger is single-dose. Men's-health protocols range from every-other-day (for TRT adjunct) to 2–3 times weekly (for hypogonadism) to once-weekly (some maintenance schedules). Daily dosing is uncommon and generally unnecessary given hCG's 24–36-hour half-life.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Ovulation trigger is single-use per cycle. TRT-adjunct use is typically continuous alongside testosterone — the rationale is that exogenous testosterone is ongoing, so the substitution for LH must be ongoing too. Fertility-induction protocols run 3–6 months minimum to allow a full spermatogenic cycle, and often 9–12 months before maximal sperm response. PCT protocols are short (2–4 weeks) and intentionally bounded.
Protocol Notes
Reconstitution of urinary-derived hCG from lyophilized powder typically uses bacteriostatic water; post-reconstitution stability is around 30 days refrigerated for most preparations. Ovidrel ships pre-filled and does not require reconstitution. Subcutaneous administration with an insulin-gauge syringe is standard for low-dose maintenance use; intramuscular is used for trigger doses and some pediatric cryptorchidism protocols. In men, the key titration question is estradiol. hCG-stimulated testosterone aromatizes into estradiol like any other testosterone, and aggressive dosing (2,000+ IU multiple times weekly) reliably raises E2 — sometimes enough to warrant an aromatase inhibitor or a dose reduction. The 500 IU every-other-day protocol is popular specifically because it is aggressive enough to maintain Leydig-cell function without driving E2 out of range in most men. In women undergoing IVF, the dose-response surface has been mapped in detail: 250 mcg recombinant hCG produces equivalent oocyte yield and pregnancy rates to 500 mcg while substantially reducing OHSS risk, so 250 mcg is the standard adult dose. Importantly: over-the-counter "homeopathic" hCG drops, pellets, or sprays marketed for weight loss are not legitimate hCG products. They either contain no hCG (homeopathic dilution) or unregulated amounts, and they were declared illegal by the FDA/FTC in 2011. Anyone considering hCG should work with a clinician using an FDA-approved product. Since March 23, 2020, hCG has been regulated as a biological product, and FDA guidance states that biological products are not eligible for the compounding exemptions in sections 503A and 503B, so hCG can no longer be compounded under those sections.
hCG has multiple FDA-approved indications (IVF trigger, hypogonadotropic hypogonadism, cryptorchidism), but its off-label use for TRT adjunct and anabolic-steroid recovery is not FDA-approved. hCG for weight loss is explicitly not FDA-approved and has been the subject of FDA enforcement action. Any use should be under the supervision of a qualified clinician.
Timeline of Effects
Onset
After a single IM or SC injection, serum hCG is detectable within 1–2 hours and peaks at 6–12 hours. Ovulation following an IVF trigger occurs at approximately 36–40 hours, which is why retrieval is timed to 34–36 hours. In men, Leydig-cell testosterone output rises within hours of injection and a single 1,500 IU IM dose can elevate plasma testosterone for 96–120 hours. Subjective effects in hypogonadal men — energy, libido, mood — are typically reported within 1–4 weeks of consistent dosing.
Peak Effect
Acute testosterone peak occurs 48–96 hours after injection in men and plateaus within 4–8 weeks on a stable regimen. Testicular volume recovery in men previously suppressed by TRT or AAS use is typically measurable by 8–12 weeks and continues to improve over 3–6 months. Spermatogenic recovery follows the full spermatogenic cycle — meaningful semen-parameter changes take 3–6 months and maximal response often takes 9–12 months of continuous gonadotropin stimulation.
After Discontinuation
hCG itself clears the system within approximately 7–10 days after the last dose given its 24–36-hour half-life. For men using hCG alongside ongoing TRT, discontinuing the hCG while continuing testosterone returns the user to the trajectory of HPG-axis suppression characteristic of TRT alone — testicular atrophy and reduced spermatogenesis resume over weeks to months. For men discontinuing both hCG and exogenous testosterone, HPG-axis recovery follows the general post-TRT / post-AAS trajectory, with prior hCG use preserving Leydig-cell responsiveness but not altering the pituitary-side recovery timeline.
Monitoring & Measurement
Bloodwork & Labs
- •Total testosterone and estradiol in men — hCG-driven testosterone aromatizes, and estradiol is the variable that most often forces a dose reduction
- •Hematocrit, which rises with any testosterone elevation and is the standard safety stop
- •LH and FSH, to document the degree of axis suppression before starting and to interpret recovery after stopping
- •Semen analysis where fertility is the reason for treatment — the only endpoint that actually answers the question
- •In women undergoing stimulation: serum estradiol, as the principal OHSS warning signal
Functional & Performance Tests
- •Testicular volume by orchidometer or ultrasound, the simplest objective marker of whether Leydig-cell stimulation is being maintained
- •Transvaginal ultrasound for follicle count and size in any ovulation-induction or IVF cycle
When to Test
In men, draw a baseline testosterone, estradiol, hematocrit, LH and FSH plus a semen analysis before starting, then recheck testosterone, estradiol and hematocrit at 6 to 8 weeks and every 6 to 12 months once stable. Semen parameters move on the spermatogenic cycle, so allow 3 months before rechecking and up to 9 to 12 months before judging maximal response. In IVF the monitoring is cycle-based and clinician-run rather than periodic.
Interpretation & Notes
The single most useful thing to understand is that serum testosterone is a poor proxy for what hCG is doing. Coviello 2005 measured intratesticular testosterone directly and found blood levels sit at roughly 1.2% of testicular levels, so a man on TRT can have a perfectly normal serum testosterone while intratesticular testosterone has fallen by 94% and spermatogenesis has stopped. That is the entire reason hCG is added. Estradiol is the practical titration lever in the other direction: if it climbs out of range, reduce the hCG dose before reaching for an aromatase inhibitor. None of this is self-directed testing — hCG is a prescription endocrine drug and the monitoring belongs with the prescribing clinician.
Common Questions
Does the hCG diet actually work?
The weight loss people experience on the Simeons "hCG diet" comes from the 500 kcal/day severe calorie restriction, not from hCG. Placebo-controlled trials (e.g., Bosch et al. 1990; Stein et al. 1976) consistently show no weight-loss advantage of hCG over saline injections when both groups eat the same very-low-calorie diet. A 1995 criteria-based meta-analysis (Lijesen et al.) drew the same conclusion. In 2011, the FDA and FTC took joint action against over-the-counter "homeopathic hCG" weight-loss products as illegal and fraudulent. A 500 kcal/day diet is the real mechanism — and carries its own risks (gallstones, electrolyte imbalance, cardiac arrhythmias) independent of any hormone.
How is hCG different from LH?
They bind the same receptor (LHCGR) and produce the same downstream Leydig-cell response, but hCG has a much longer plasma half-life — roughly 24–36 hours versus 20 minutes for LH — because of additional glycosylation on its beta-subunit carboxy-terminal extension. Clinically this means a single hCG injection produces a sustained LH-like stimulus lasting days, which is why it works as a convenient IVF ovulation trigger and as a periodic injection for men rather than a continuous infusion. It is not identical to LH, but functionally it is an LH-receptor agonist.
Why do men on TRT use hCG alongside testosterone?
Exogenous testosterone suppresses the hypothalamic–pituitary–gonadal axis, which shuts off endogenous LH and therefore shuts off Leydig-cell stimulation. That leads to testicular atrophy and, in roughly 40% of men on TRT, to azoospermia — a figure that comes from the Hsieh 2013 series cited below. Low-dose hCG replaces the LH signal directly at the testis, maintaining intratesticular testosterone at levels necessary for spermatogenesis. Coviello et al. (2005) showed that 250–500 IU every other day kept intratesticular testosterone near or above baseline, and in the Hsieh et al. (2013) series, 500 IU given intramuscularly every other day preserved semen parameters. Men who want to preserve fertility or testicular volume during TRT commonly use this approach, under clinician supervision.
Is hCG FDA-approved?
Yes — hCG has multiple FDA-approved products. Ovidrel (choriogonadotropin alfa, recombinant) is approved for inducing final follicular maturation and ovulation in IVF. Pregnyl and Novarel (urinary-derived hCG) are approved for ovulation induction, cryptorchidism in prepubertal boys, and hypogonadotropic hypogonadism in men. What is not FDA-approved is hCG for weight loss — the agency has explicitly acted against that marketing, and compounded or over-the-counter hCG diet products are illegal in the US.
Can hCG restart natural testosterone after a steroid cycle?
It can stimulate Leydig cells acutely, and it is commonly used in post-cycle therapy (PCT) protocols after anabolic-androgenic steroid use — often combined with a SERM like clomiphene or tamoxifen. The 2014 Rahnema review and subsequent literature support hCG plus SERM as standard management for anabolic-steroid-induced hypogonadism, and case series show high rates of sperm recovery. But randomized controlled data specifically for PCT protocols are thin, recovery is variable, and men who have used high-dose AAS for years may have prolonged or incomplete recovery regardless of intervention.
What is a 'dual trigger' in IVF?
A dual trigger combines hCG with a GnRH agonist (typically leuprolide) at the final maturation step of an IVF stimulation cycle, instead of using hCG alone. The GnRH agonist component induces a brief endogenous LH/FSH surge that more closely mimics physiological ovulation, while the hCG component provides sustained LH-receptor stimulation supporting corpus luteum function. Dual triggering is most commonly used in poor responders, in women with diminished ovarian reserve, and to reduce the OHSS risk associated with high-dose hCG-only triggers. The 2026 evidence is more equivocal than the enthusiasm suggests. A single-blind randomized trial in diminished ovarian reserve found dual triggering produced significantly more total oocytes, metaphase II oocytes, good-quality embryos and a higher implantation rate — but no significant difference in clinical pregnancy or miscarriage rates. A 2026 cycle-based analysis of 1,824 POSEIDON group 4 cycles found dual triggering did not improve mature oocyte yield or clinical outcomes at all. And while dual triggering lowers OHSS risk relative to an hCG-only trigger, a 2026 systematic review found it carries a higher incidence of moderate-to-severe OHSS than a GnRH-agonist-only trigger (odds ratio 12.33, 95% CI 3.30–46.04), so the OHSS advantage depends entirely on which comparator you have in mind.
Are there long-term consequences for children conceived after high-dose hCG IVF triggers?
It's an emerging research question, not a settled clinical issue. A 2026 Nature Communications study reported that higher trigger-day hCG doses associated with reduced global DNA methylation in peripheral blood of ART-conceived children versus naturally conceived comparators, and described links between elevated maternal trigger doses and neurodevelopmental risk markers in a cohort of 1,333 singleton offspring. The human arms are observational and confounded by the many other differences between ART and natural conception, and they should not lead to wholesale changes in IVF triggering practice. The paper is stronger than a pure association study, though: in mice, transient hCG exposure impaired offspring neurocognitive behaviour, reduced hippocampal dentate gyrus neurogenesis and downregulated the histone methyltransferase EHMT1 — and microinjecting EHMT1 messenger RNA into exposed zygotes restored both neurogenesis and behaviour, which is a mechanistic rescue rather than a correlation. They do however reinforce the trend toward using the lowest effective hCG trigger dose (250 mcg recombinant, or GnRH agonist / dual triggering in appropriate patients) rather than 500 mcg or higher, both for OHSS reduction and for prudence about cumulative offspring exposure.
Who hCG Is NOT For
- •Known hypersensitivity to hCG or to excipients in the specific product — anaphylactoid reactions have been reported.
- •Hormone-sensitive malignancy — prostate cancer, testicular cancer, and certain hormone-sensitive breast cancers, where hCG-driven testosterone or estrogen elevation is contraindicated.
- •Precocious puberty or a known pituitary tumor — hCG stimulation in these contexts requires specialist management, not empirical use.
- •Ovarian cysts or ovarian enlargement not due to polycystic ovary syndrome — risk of further enlargement and rupture.
- •Uncontrolled thyroid or adrenal dysfunction — these axes should be stabilized before reproductive-axis stimulation.
- •Pregnancy — hCG is not indicated as a therapeutic during established pregnancy (it is used pre-conception as an ovulation trigger); exogenous administration during pregnancy is not appropriate.
- •Severe cardiovascular, renal, or hepatic disease — the fluid-shift and hormonal consequences of OHSS in women or testosterone elevation in men may be poorly tolerated.
- •Weight loss — the FDA has explicitly determined hCG is not appropriate therapy for weight loss; this is not a medical contraindication in the narrow sense but is a regulatory one.
Drug & Supplement Interactions
hCG's pharmacodynamic interactions are centered on the reproductive axis. The most important practical interaction is with exogenous testosterone in men: the entire therapeutic rationale of adding hCG to TRT rests on hCG substituting for the suppressed LH signal, and dosing must be calibrated against the TRT dose, frequency, and measured response. Combining hCG with GnRH agonists or antagonists (leuprolide, goserelin, cetrorelix) is generally counterproductive — the GnRH drug is designed to suppress gonadotropin activity, which hCG then partially restores downstream of the block. Aromatase inhibitors (anastrozole, letrozole) are often paired with hCG in men to control the estradiol rise that hCG-driven testosterone production produces; this is standard off-label practice but should be dose-titrated to measured E2. SERMs (clomiphene, tamoxifen, enclomiphene) are frequently combined with hCG in post-cycle therapy and in fertility induction, acting upstream to raise endogenous gonadotropins while hCG acts directly on the Leydig cell. In women undergoing IVF, hCG interacts with the FSH preparation and GnRH antagonist protocol used during stimulation — the interaction is the intended protocol and is managed by the reproductive endocrinologist. Concurrent high-dose glucocorticoids may blunt the hCG-stimulated gonadal response. Drugs known to suppress spermatogenesis independently (cytotoxic chemotherapy, certain antiepileptics, high-dose opioids) may limit the response to hCG in men. hCG interferes with pregnancy-test results because pregnancy tests detect hCG itself — this is a laboratory, not a pharmacologic, interaction but is worth noting for users.
Safety Profile
Common Side Effects
Cautions
- • Ovarian hyperstimulation syndrome (OHSS) is the principal dose-limiting risk in women undergoing IVF — 500 mcg recombinant doses have been associated with higher OHSS rates than 250 mcg
- • In men, hCG raises estradiol via aromatization and may require concurrent aromatase-inhibitor management
- • Contraindicated in hormone-sensitive malignancy (prostate, certain breast cancers, testicular cancer)
- • Over-the-counter "homeopathic hCG" weight-loss products were declared illegal by the FDA/FTC in 2011 — any such products on the market are unauthorized
- • Prohibited by WADA for male athletes at all times under S2.2.1, 'Testosterone-stimulating peptides in males'; the class does not apply to female athletes
- • hCG has been regulated as a biological product since March 23, 2020, so it cannot be compounded under sections 503A or 503B — use an FDA-approved product
What We Don't Know
Long-term safety of chronic low-dose hCG as a TRT adjunct, over years rather than months, is not well characterized in controlled trials. Optimal hCG dosing for post-cycle recovery after long-term anabolic steroid use remains empirical. Any weight-loss effect of hCG above and beyond calorie restriction has been actively searched for and not found — the honest answer there is not 'unknown' but 'debunked.'
Legal Status
United States
hCG is FDA-approved as multiple prescription products: Ovidrel (choriogonadotropin alfa, recombinant) for IVF ovulation trigger; Pregnyl and Novarel (urinary-derived hCG) for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism in men. Prescription use is legal under these labels. On March 23, 2020, these products moved from drug approvals (NDAs) to biologics licenses (BLAs) under the Biologics Price Competition and Innovation Act, and because biological products are not eligible for the compounding exemptions in sections 503A and 503B, hCG can no longer be compounded. Off-label use for TRT adjunct and post-cycle therapy is common but not FDA-approved. Over-the-counter "homeopathic" hCG drops, pellets, and sprays for weight loss were declared illegal by the FDA and FTC in 2011 and are subject to seizure and enforcement. hCG is not a controlled substance at the federal level, though some states have specific restrictions.
International
hCG products are approved in essentially every major regulatory jurisdiction for ovulation induction and male hypogonadism indications. EMA-approved products include Ovitrelle (the EU name for Ovidrel), Pregnyl, and various generic urinary preparations. Availability and labeling for cryptorchidism and PCT/TRT-adjunct use varies by country.
Sports & Competition
hCG (chorionic gonadotrophin) is prohibited for male athletes at all times (in and out of competition) by WADA under class S2.2.1, 'Testosterone-stimulating peptides in males', because it stimulates endogenous testosterone production; the wording is the same in the 2026 and 2027 Lists. The class applies to males only, so the prohibition does not apply to female athletes. Male athletes subject to WADA code, USADA, UKAD, or equivalent anti-doping bodies must treat hCG as prohibited regardless of therapeutic intent; Therapeutic Use Exemptions are evaluated case by case.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
The hCG diet works because hCG specifically burns abnormal fat.
Reality
Repeatedly tested and repeatedly disproven. Placebo-controlled trials (Stein 1976; Bosch 1990) and a 1995 criteria-based meta-analysis (Lijesen et al., British Journal of Clinical Pharmacology) all found hCG no better than saline when both groups ate the same 500 kcal/day diet. The weight loss is entirely from the calorie restriction. The FDA and FTC took joint enforcement action in 2011 declaring over-the-counter "homeopathic hCG" weight-loss products illegal and fraudulent.
Myth
hCG and LH are the same thing.
Reality
They bind the same receptor and produce similar downstream effects, but they are distinct proteins with different pharmacokinetics. hCG has a glycosylated carboxy-terminal extension on its beta-subunit that gives it a plasma half-life of 24–36 hours versus LH's ~20 minutes. That is why a single hCG injection can sustain a Leydig-cell response for days, while LH needs continuous pulsatile secretion.
Myth
Homeopathic hCG drops and pellets are a safer, easier alternative to injections.
Reality
Homeopathic hCG products either contain essentially no hCG (by the definition of homeopathic dilution) or unregulated amounts, and none have demonstrated weight-loss efficacy beyond the accompanying very-low-calorie diet. The FDA and FTC declared them illegal in 2011. Legitimate hCG is an injectable prescription drug.
Myth
hCG causes testicular atrophy.
Reality
The opposite is true. Exogenous testosterone suppresses LH and withdraws the signal that keeps Leydig cells working, which is what drives testicular atrophy; hCG mimics LH and maintains Leydig-cell stimulation directly. The clearest evidence is functional rather than anatomical: in the La Vignera 2016 randomized comparison of hCG against three testosterone formulations in late-onset hypogonadism, every testosterone arm showed a significant fall in sperm density and in progressively motile sperm relative to the hCG group, while the hCG group also ran lower hematocrit, PSA and prostate volume. That trial did not actually measure testicular volume, so the strongest direct support for volume preservation comes instead from Coviello 2005, where 500 IU of hCG every other day held intratesticular testosterone 26% above baseline in men whose gonadotropins were fully suppressed by testosterone.
Myth
hCG is a weight-loss drug.
Reality
hCG has multiple legitimate endocrine indications — ovulation trigger in IVF, hypogonadotropic hypogonadism in men, cryptorchidism in boys — but weight loss is not among them. The FDA explicitly states there is no substantial evidence that hCG produces weight loss beyond the caloric restriction that accompanies it, and hCG is not approved for any weight-loss indication.
Myth
hCG can fully restart natural testosterone after any anabolic steroid cycle.
Reality
hCG can reliably stimulate Leydig cells in the short term and is part of standard PCT protocols, but full recovery of the HPG axis — including pituitary LH and FSH secretion — depends on duration and dose of prior steroid use, baseline testicular reserve, and time. Men who have used high-dose AAS for years may have prolonged or incomplete recovery regardless of hCG or SERM therapy.
Published Research
15 studiesGnRH Agonist with Low-Dose hCG (Dual Trigger) versus GnRH Agonist Only Trigger in High Responders in GnRH Antagonist Cycle: A Systematic Review and Meta-Analysis
Trigger-day hCG effects on DNA methylation and neurodevelopment in ART offspring (Nat Commun, 2026)
Nature Communications 2026 study reporting that higher trigger-day hCG dose was associated with reduced global DNA methylation in peripheral blood of ART-conceived offspring versus naturally conceived children, with a larger cohort of 1,333 singleton offspring suggesting links between elevated maternal trigger hCG doses and neurodevelopmental risks. Early signal raising questions about long-term offspring consequences of high-dose hCG triggering in IVF.
Effect of dual trigger on pregnancy outcomes in women with diminished ovarian reserve: A single-blind randomized clinical trial
Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility
Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles
Cochrane review of 18 randomized trials and 2,952 women comparing recombinant hCG or recombinant LH against urinary hCG as the final maturation trigger. It found no evidence of a difference for live birth, ongoing pregnancy or OHSS. The practical reading is that the choice between recombinant and urinary trigger products is a matter of cost, convenience and supply rather than outcome.
Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone
Anabolic steroid–induced hypogonadism: diagnosis and treatment
Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy
Hsieh et al. — 26 men on TRT plus 500 IU hCG every other day; no patient became azoospermic, and 9 contributed to a pregnancy during follow-up.
Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression
Coviello et al. 2005, the dose-finding study every hCG-with-TRT protocol traces back to. Twenty-nine men received 200 mg testosterone enanthate weekly plus saline or 125, 250 or 500 IU hCG every other day for 3 weeks, with intratesticular testosterone measured directly by fine-needle aspiration. Testosterone alone suppressed intratesticular testosterone by 94%; adding hCG restored it linearly with dose, ending 25% below baseline at 125 IU, 7% below at 250 IU and 26% above at 500 IU. The study also quantifies why this matters at all: baseline serum testosterone is just 1.2% of the intratesticular concentration, so normal blood levels say nothing about the environment spermatogenesis actually needs.
The action of chorionic gonadotrophin in the obese
The effect of human chorionic gonadotropin (hCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis
Lijesen et al. 1995, British Journal of Clinical Pharmacology — criteria-based meta-analysis concluding there is no scientific evidence hCG causes weight loss, redistributes fat, reduces hunger, or induces wellbeing beyond caloric restriction.
Human chorionic gonadotrophin and weight loss. A double-blind, placebo-controlled trial
Ineffectiveness of human chorionic gonadotropin in weight reduction: a double-blind study
FDA: List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020
FDA guidance: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application
Quick Facts
- Class
- Gonadotropin / LH Receptor Agonist
- Tier
- B
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Nov 2026
- Citations
- 15PubMed
Also known as
Tags
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.